Abivax

Abivax is a clinical-stage biotechnology company based in France that was established in 2014. The company is focused on regulating the immune response through the power of microRNA, with a particular emphasis on its lead candidate obefazimod, a molecule that enhances the expression of miR-124 to stabilize the immune response and treat chronic inflammatory diseases.